BRAF and non-cutaneous melanoma: Because mutations in c-KIT (and BRAF) are now being successfully exploited by new targeted therapies, it would appear appropriate to perform relevant mutation testing of primary extracutaneous melanoma in patients in whom systemic treatment is being considered.